For clinician-administered drugs, researchers find no association between price increases and OOP cost increases
It seems obvious to assume that patient out-of-pocket costs would increase as drug companies raise the prices of their drugs. But a new study published yesterday in Health Services Research from Harvard Medical School authors shows that for one major class of drugs, the story is more complicated.
From 2009 to 2018, the prices of drugs that were administered by doctors, as opposed to ones patients take themselves, rose 4.4% per year. And at the same time, patients’ median out-of-pocket costs increased 9.6% per year, accounting for inflation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
